Compare Stocks: ACET, ADMA, CMPX, and IPSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$6.90 -23.5%	$8.85	$6.01 ▼ $17.44	$65.06M	1.58	137,251 shs	1.30 million shs
ADMA ADMA Biologics	$9.67 +3.0%	$9.28	$7.21 ▼ $20.46	$2.15B	0.78	4.23 million shs	707,378 shs
CMPX Compass Therapeutics	$1.11 -2.2%	$2.09	$1.10 ▼ $6.88	$199.00M	0.95	4.56 million shs	1.65 million shs
IPSC Century Therapeutics	$1.67 -0.3%	$2.01	$0.44 ▼ $3.04	$299.67M	1.59	1.27 million shs	126,236 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-1.74%	-0.44%	+5.37%	-32.89%
ADMA ADMA Biologics	0.00%	+2.96%	+0.43%	+12.07%	-39.91%
CMPX Compass Therapeutics	0.00%	-40.53%	-52.92%	-47.69%	-69.79%
IPSC Century Therapeutics	0.00%	-10.22%	-17.73%	-30.71%	+228.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$6.90 -23.5%	$8.85	$6.01 ▼ $17.44	$65.06M	1.58	137,251 shs	1.30 million shs
ADMA ADMA Biologics	$9.67 +3.0%	$9.28	$7.21 ▼ $20.46	$2.15B	0.78	4.23 million shs	707,378 shs
CMPX Compass Therapeutics	$1.11 -2.2%	$2.09	$1.10 ▼ $6.88	$199.00M	0.95	4.56 million shs	1.65 million shs
IPSC Century Therapeutics	$1.67 -0.3%	$2.01	$0.44 ▼ $3.04	$299.67M	1.59	1.27 million shs	126,236 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	0.00%	-1.74%	-0.44%	+5.37%	-32.89%
ADMA ADMA Biologics	0.00%	+2.96%	+0.43%	+12.07%	-39.91%
CMPX Compass Therapeutics	0.00%	-40.53%	-52.92%	-47.69%	-69.79%
IPSC Century Therapeutics	0.00%	-10.22%	-17.73%	-30.71%	+228.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.88	Moderate Buy	$46.80	418.85% Upside
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	99.00% Upside
CMPX Compass Therapeutics	2.76	Moderate Buy	$10.21	803.92% Upside
IPSC Century Therapeutics	2.43	Hold	$4.75	184.43% Upside

Current Analyst Ratings Breakdown

Latest ACET, ADMA, CMPX, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CMPX Compass Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/23/2026	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00
9/23/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
9/23/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/23/2026	CMPX Compass Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$4.00
9/22/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$5.00 ➝ $1.00
9/22/2026	CMPX Compass Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/18/2026	ACET Adicet Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$27.00
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	ACET Adicet Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
ADMA ADMA Biologics	$510.17M	4.12	$0.65 per share	14.34	$2.01 per share	4.67
CMPX Compass Therapeutics	$850K	239.41	N/A	N/A	$1.11 per share	1.02
IPSC Century Therapeutics	$109.16M	2.77	$0.01 per share	125.56	$1.82 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	13.40	11.04	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
IPSC Century Therapeutics	-$9.58M	-$0.93	N/A	N/A	N/A	N/A	-49.51%	-38.09%	11/12/2026 (Estimated)

Latest ACET, ADMA, CMPX, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	-$0.17	-$0.06	-$0.17	$2.17 million	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
ADMA ADMA Biologics	0.49	6.97	3.81
CMPX Compass Therapeutics	N/A	11.22	11.22
IPSC Century Therapeutics	N/A	8.28	8.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
ADMA ADMA Biologics	75.68%
CMPX Compass Therapeutics	68.43%
IPSC Century Therapeutics	50.20%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
ADMA ADMA Biologics	3.90%
CMPX Compass Therapeutics	18.70%
IPSC Century Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	102	9.36 million	9.04 million	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Not Optionable
IPSC Century Therapeutics	78	181.07 million	176.73 million	Optionable

ACET, ADMA, CMPX, and IPSC Headlines

Recent News About These Companies

Stocktwits Pharma Pulse: Lilly, Novo lead a busy week — here are the stocks and readouts to watch

September 27 at 12:49 AM | msn.com

Century Therapeutics stock falls 6.88 percent as milestones approach

September 24, 2026 | ad-hoc-news.deA

Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Analysts

September 23, 2026 | americanbankingnews.com

Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months

September 21, 2026 | ad-hoc-news.deA

Century Therapeutics stock falls as IPSC trades near 52-week low

September 19, 2026 | ad-hoc-news.deA

Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Hold" by Brokerages

September 18, 2026 | marketbeat.com

Century Therapeutics (NASDAQ:IPSC) Upgraded to Hold at Wall Street Zen

September 12, 2026 | marketbeat.com

Century Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing

September 10, 2026 | rttnews.com

Century Therapeutics Appoints Joseph Truitt to Board of Directors

September 9, 2026 | globenewswire.com

BlackRock Inc. Makes New $19.82 Million Investment in Century Therapeutics, Inc. $IPSC

September 3, 2026 | marketbeat.com

Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 12, 2026 | finanznachrichten.de

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 12, 2026 | globenewswire.com

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

July 14, 2026 | insidermonkey.com

Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential

July 9, 2026 | seekingalpha.com

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

July 9, 2026 | globenewswire.com

Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation

June 13, 2026 | finance.yahoo.com

Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813

June 10, 2026 | insidermonkey.com

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

June 8, 2026 | globenewswire.com

Mizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendation

May 28, 2026 | msn.com

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

May 14, 2026 | globenewswire.com

Century Therapeutics Reports First Quarter Financial Results and Business Updates

May 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, CMPX, and IPSC Company Descriptions

Adicet Bio NASDAQ:ACET

$6.90 -2.12 (-23.50%)

As of 12:20 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ADMA Biologics NASDAQ:ADMA

$9.66 +0.29 (+3.04%)

As of 12:20 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Compass Therapeutics NASDAQ:CMPX

$1.10 -0.03 (-2.21%)

As of 12:21 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Century Therapeutics NASDAQ:IPSC

$1.66 -0.01 (-0.30%)

As of 12:20 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, CMPX, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, CMPX, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, CMPX, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, CMPX, and IPSC Company Descriptions

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Compass Therapeutics NASDAQ:CMPX

Century Therapeutics NASDAQ:IPSC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, CMPX, and IPSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, CMPX, and IPSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, CMPX, and IPSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, CMPX, and IPSC Company Descriptions

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Compass Therapeutics NASDAQ:CMPX

Century Therapeutics NASDAQ:IPSC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools